Business Description
Vifor Pharma AG
ISIN : CH0364749348
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.69 | |||||
Equity-to-Asset | 0.68 | |||||
Debt-to-Equity | 0.17 | |||||
Debt-to-EBITDA | 0.91 | |||||
Interest Coverage | 39.56 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 7.89 | |||||
Beneish M-Score | -3.04 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.4 | |||||
3-Year EBITDA Growth Rate | 16.1 | |||||
3-Year EPS without NRI Growth Rate | 1.2 | |||||
3-Year Book Growth Rate | 7.2 | |||||
Future 3-5Y Total Revenue Growth Rate | 6.91 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
6-1 Month Momentum % | -0.23 | |||||
12-1 Month Momentum % | 5.09 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.91 | |||||
Quick Ratio | 1.56 | |||||
Cash Ratio | 1.01 | |||||
Days Inventory | 198.26 | |||||
Days Sales Outstanding | 87.24 | |||||
Days Payable | 81.91 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.2 | |||||
Dividend Payout Ratio | 0.89 | |||||
Forward Dividend Yield % | 1.2 | |||||
5-Year Yield-on-Cost % | 1.2 | |||||
Shareholder Yield % | 1.48 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 63.17 | |||||
Operating Margin % | 19.53 | |||||
Net Margin % | 7.96 | |||||
FCF Margin % | 16.92 | |||||
ROE % | 4.13 | |||||
ROA % | 2.83 | |||||
ROIC % | 7.38 | |||||
ROC (Joel Greenblatt) % | 56 | |||||
ROCE % | 7.25 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 78.66 | |||||
PE Ratio without NRI | 77.55 | |||||
Shiller PE Ratio | 35.39 | |||||
Price-to-Owner-Earnings | 37.41 | |||||
PEG Ratio | 4.19 | |||||
PS Ratio | 6.26 | |||||
PB Ratio | 3.29 | |||||
Price-to-Tangible-Book | 9.77 | |||||
Price-to-Free-Cash-Flow | 37.02 | |||||
Price-to-Operating-Cash-Flow | 21.67 | |||||
EV-to-EBIT | 34.16 | |||||
EV-to-EBITDA | 17.15 | |||||
EV-to-Revenue | 6.02 | |||||
EV-to-FCF | 35.64 | |||||
Price-to-Projected-FCF | 2.6 | |||||
Price-to-Median-PS-Value | 1.74 | |||||
Price-to-Peter-Lynch-Fair-Value | 4.71 | |||||
Price-to-Graham-Number | 5.66 | |||||
Price-to-Net-Current-Asset-Value | 40.13 | |||||
Earnings Yield (Greenblatt) % | 2.93 | |||||
FCF Yield % | 2.86 | |||||
Forward Rate of Return (Yacktman) % | 19.39 |